vs
ACADIA PHARMACEUTICALS INC（ACAD）与Apellis Pharmaceuticals, Inc.（APLS）财务数据对比。点击上方公司名可切换其他公司
ACADIA PHARMACEUTICALS INC的季度营收约是Apellis Pharmaceuticals, Inc.的1.4倍（$284.0M vs $199.9M），ACADIA PHARMACEUTICALS INC净利率更高（96.3% vs -29.5%，领先125.8%），ACADIA PHARMACEUTICALS INC同比增速更快（9.4% vs -5.9%），过去两年ACADIA PHARMACEUTICALS INC的营收复合增速更高（17.5% vs 7.7%）
阿卡迪亚制药是一家总部位于美国加利福尼亚州圣地亚哥德尔马地区的生物制药企业，专注于中枢神经系统相关疾病治疗药物的研发、生产与商业化，致力于为全球患者提供创新的临床治疗方案。
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
ACAD vs APLS — 直观对比
营收规模更大
ACAD
是对方的1.4倍
$199.9M
营收增速更快
ACAD
高出15.3%
-5.9%
净利率更高
ACAD
高出125.8%
-29.5%
两年增速更快
ACAD
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $284.0M | $199.9M |
| 净利润 | $273.6M | $-59.0M |
| 毛利率 | 90.8% | — |
| 营业利润率 | 6.1% | -25.6% |
| 净利率 | 96.3% | -29.5% |
| 营收同比 | 9.4% | -5.9% |
| 净利润同比 | 90.3% | -62.2% |
| 每股收益（稀释后） | $1.61 | $-0.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACADAPLS
| Q4 25 | $284.0M | $199.9M | ||
| Q3 25 | $278.6M | $458.6M | ||
| Q2 25 | $264.6M | $178.5M | ||
| Q1 25 | $244.3M | $166.8M | ||
| Q4 24 | $259.6M | $212.5M | ||
| Q3 24 | $250.4M | $196.8M | ||
| Q2 24 | $242.0M | $199.7M | ||
| Q1 24 | $205.8M | $172.3M |
净利润ACADAPLS
| Q4 25 | $273.6M | $-59.0M | ||
| Q3 25 | $71.8M | $215.7M | ||
| Q2 25 | $26.7M | $-42.2M | ||
| Q1 25 | $19.0M | $-92.2M | ||
| Q4 24 | $143.7M | $-36.4M | ||
| Q3 24 | $32.8M | $-57.4M | ||
| Q2 24 | $33.4M | $-37.7M | ||
| Q1 24 | $16.6M | $-66.4M |
毛利率ACADAPLS
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — | ||
| Q1 24 | 88.8% | — |
营业利润率ACADAPLS
| Q4 25 | 6.1% | -25.6% | ||
| Q3 25 | 12.8% | 48.7% | ||
| Q2 25 | 12.2% | -18.6% | ||
| Q1 25 | 7.9% | -50.0% | ||
| Q4 24 | 59.1% | -12.3% | ||
| Q3 24 | 12.6% | -24.0% | ||
| Q2 24 | 12.6% | -14.7% | ||
| Q1 24 | 7.4% | -36.0% |
净利率ACADAPLS
| Q4 25 | 96.3% | -29.5% | ||
| Q3 25 | 25.8% | 47.0% | ||
| Q2 25 | 10.1% | -23.6% | ||
| Q1 25 | 7.8% | -55.3% | ||
| Q4 24 | 55.4% | -17.1% | ||
| Q3 24 | 13.1% | -29.2% | ||
| Q2 24 | 13.8% | -18.9% | ||
| Q1 24 | 8.0% | -38.5% |
每股收益（稀释后）ACADAPLS
| Q4 25 | $1.61 | $-0.40 | ||
| Q3 25 | $0.42 | $1.67 | ||
| Q2 25 | $0.16 | $-0.33 | ||
| Q1 25 | $0.11 | $-0.74 | ||
| Q4 24 | $0.86 | $-0.30 | ||
| Q3 24 | $0.20 | $-0.46 | ||
| Q2 24 | $0.20 | $-0.30 | ||
| Q1 24 | $0.10 | $-0.54 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $177.7M | $466.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.2B | $370.1M |
| 总资产 | $1.6B | $1.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ACADAPLS
| Q4 25 | $177.7M | $466.2M | ||
| Q3 25 | $258.0M | $479.2M | ||
| Q2 25 | $253.6M | $370.0M | ||
| Q1 25 | $217.7M | $358.4M | ||
| Q4 24 | $319.6M | $411.3M | ||
| Q3 24 | $155.1M | $396.9M | ||
| Q2 24 | $177.1M | $360.1M | ||
| Q1 24 | $204.7M | $325.9M |
总债务ACADAPLS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $93.1M |
股东权益ACADAPLS
| Q4 25 | $1.2B | $370.1M | ||
| Q3 25 | $917.3M | $401.2M | ||
| Q2 25 | $822.4M | $156.3M | ||
| Q1 25 | $765.2M | $164.2M | ||
| Q4 24 | $732.8M | $228.5M | ||
| Q3 24 | $577.2M | $237.1M | ||
| Q2 24 | $516.7M | $264.3M | ||
| Q1 24 | $464.0M | $266.7M |
总资产ACADAPLS
| Q4 25 | $1.6B | $1.1B | ||
| Q3 25 | $1.3B | $1.1B | ||
| Q2 25 | $1.2B | $821.4M | ||
| Q1 25 | $1.1B | $807.3M | ||
| Q4 24 | $1.2B | $885.1M | ||
| Q3 24 | $976.9M | $901.9M | ||
| Q2 24 | $914.1M | $904.5M | ||
| Q1 24 | $855.1M | $831.9M |
负债/权益比ACADAPLS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.35× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-48.7M | $-14.2M |
| 自由现金流经营现金流 - 资本支出 | — | $-14.3M |
| 自由现金流率自由现金流/营收 | — | -7.1% |
| 资本支出强度资本支出/营收 | — | 0.1% |
| 现金转化率经营现金流/净利润 | -0.18× | — |
| 过去12个月自由现金流最近4个季度 | — | $45.0M |
8季度趋势，按日历期对齐
经营现金流ACADAPLS
| Q4 25 | $-48.7M | $-14.2M | ||
| Q3 25 | $74.3M | $108.5M | ||
| Q2 25 | $64.0M | $4.4M | ||
| Q1 25 | $20.3M | $-53.4M | ||
| Q4 24 | $40.4M | $19.4M | ||
| Q3 24 | $63.2M | $34.1M | ||
| Q2 24 | $25.0M | $-8.3M | ||
| Q1 24 | $29.1M | $-133.0M |
自由现金流ACADAPLS
| Q4 25 | — | $-14.3M | ||
| Q3 25 | $73.9M | $108.3M | ||
| Q2 25 | — | $4.4M | ||
| Q1 25 | — | $-53.4M | ||
| Q4 24 | — | $19.3M | ||
| Q3 24 | $63.2M | — | ||
| Q2 24 | — | $-8.4M | ||
| Q1 24 | — | $-133.3M |
自由现金流率ACADAPLS
| Q4 25 | — | -7.1% | ||
| Q3 25 | 26.5% | 23.6% | ||
| Q2 25 | — | 2.5% | ||
| Q1 25 | — | -32.0% | ||
| Q4 24 | — | 9.1% | ||
| Q3 24 | 25.2% | — | ||
| Q2 24 | — | -4.2% | ||
| Q1 24 | — | -77.3% |
资本支出强度ACADAPLS
| Q4 25 | — | 0.1% | ||
| Q3 25 | 0.1% | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | 0.0% | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.2% |
现金转化率ACADAPLS
| Q4 25 | -0.18× | — | ||
| Q3 25 | 1.03× | 0.50× | ||
| Q2 25 | 2.40× | — | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 1.93× | — | ||
| Q2 24 | 0.75× | — | ||
| Q1 24 | 1.76× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
